Ng H

Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology.

Laurén I, Havervall S, Ng H, ..., Thålin C, Mangsbo S

Immun Inflamm Dis 10 (4) e595 [2022-04-00; online 2022-03-30]

Gustaf Christoffersson SciLifeLab Fellow

Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines.

Marking U, Havervall S, Greilert-Norin N, ..., Åberg M, Thålin C

Vaccines (Basel) 10 (3) - [2022-02-24; online 2022-02-24]

SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection.

Havervall S, Jernbom Falk A, Klingström J, ..., Nilsson P, Thålin C

PLoS ONE 17 (1) e0262169 [2022-01-12; online 2022-01-12]

Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.

Havervall S, Ng H, Jernbom Falk A, ..., Hober S, Thålin C

J. Intern. Med. 291 (1) 72-80 [2022-01-00; online 2021-09-27]

SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden.

Rudberg AS, Havervall S, Månberg A, ..., Hober S, Thålin C

Nat Commun 11 (1) 5064 [2020-10-08; online 2020-10-08]